Get the Stockscreener App
2.89
4.33%
0.12
After Hours:
2.89
Xenetic Biosciences Inc stock is traded at $2.89, with a volume of 2,759.
It is up +4.33% in the last 24 hours and up +17.24% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
See More
Previous Close:
$2.77
Open:
$2.815
24h Volume:
2,759
Relative Volume:
0.42
Market Cap:
$4.32M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.0509
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
+3.21%
1M Performance:
+17.24%
6M Performance:
-23.65%
1Y Performance:
-32.32%
1-Day Range:
$2.78
$2.89
1-Week Range:
$2.6612
$2.9218
52-Week Range:
$2.20
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.89 | 4.32M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Appoints Accomplished Biopharmaceutical Executive, Greg MacMichael, Ph.D. to Scientific Advisory Board - ACCESS Newswire
Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM) - ACCESS Newswire
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Analyzing Ampio Pharmaceuticals (NYSE:AMPE) & Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences (NASDAQ:XBIO) Earns Neutral Rating from HC Wainwright - Defense World
Xenetic Biosciences appoints new accounting firm By Investing.com - Investing.com Canada
Xenetic Biosciences appoints new accounting firm - Investing.com
Wainwright maintains Neutral on Xenetic shares after segment - Investing.com
Wainwright maintains Neutral on Xenetic shares after segment By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc. Releases Virtual Investor "What This M - GuruFocus
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - guardonline.com
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):